Close

Search

Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
share
Email Facebook Twitter Google+ LinkedIn Comments

Imaging Tracer Allows Early Evaluation of Abdominal Aortic Aneurysm

BioPhotonics
Oct 2017
NEW HAVEN, Conn. — With the development of a novel tracer, single-photon emission computed tomography/computed tomography (SPECT/CT) imaging could potentially be used to assess a patient’s rupture risk for abdominal aortic aneurysm (AAA), allowing better management of this disease.

Novel imaging tracer for detecting risk of abdominal aortic aneurysm, Yale University.

Examples of ex vivo photography (A) and autoradiography (B) of aortae and carotid arteries from apoE-/-mice with CaCl2-induced carotid aneurysm injected with 99mTc-RYM1 without (left) and with the pre-injection of an excess of MMP inhibitor, RYM (right). Courtesy of Jakub Toczek et al., Yale Cardiovascular Research Center, New Haven, Conn.

Researchers developed a water-soluble matrix metalloproteinase (MMP) inhibitor that formed the basis for a novel tracer, RYM1. The new tracer was compared with another MMP tracer in mouse models of aneurysm. 

The study results showed that SPECT/CT imaging used with the new tracer, RYM1 labeled with Tc-99m, showed promise as a tool for managing AAA. 

“Studies in mouse models of aneurysm showed that this tracer allows for imaging vessel wall biology with high sensitivity and specificity, and aortic tracer uptake in vivo correlates with vessel wall inflammation,” said Mehran M. Sadeghi, M.D., Yale Cardiovascular Research Center.

“There is no effective medical therapy for AAA, and current guidelines recommend invasive repair of large AAA. However, the morbidity and mortality remain high, so better tools for AAA risk stratification are needed,” Sadeghi said.

Looking ahead, he added, “Fulfilling the potential of molecular imaging in improving patient care and advancing research is critically dependent on the development of novel tracers with real potential for clinical translation. . . . Further development of RYM1-based imaging could expand the applications of molecular imaging and nuclear medicine, and improve patient management in a wide range of diseases.”

The research was published in The Journal of Nuclear Medicine (doi: 10.2967/jnumed.116.188656). 

Research & TechnologyeducationAmericasimagingmedicalmolecular imagingSPECT/CTsingle photon emission computed tomographyaneurysmbiophotonicsBioScan

Comments
Terms & Conditions Privacy Policy About Us Contact Us
back to top

Facebook Twitter Instagram LinkedIn YouTube RSS
©2017 Photonics Media
x Subscribe to BioPhotonics magazine - FREE!